The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Hemophilia A Gene Therapy: Valoctocogene Roxaparvovec

AAV-based gene therapy revolutionizing severe hemophilia A management

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Hemophilia A Gene Therapy: Valoctocogene Roxaparvovec?

Valoctocogene roxaparvovec uses AAV5 viral vector to deliver functional B-domain deleted factor VIII gene to hepatocytes.

Single intravenous infusion produces durable factor VIII expression eliminating need for prophylactic factor concentrate infusions.

Pre-treatment screening for pre-existing AAV5 neutralizing antibodies excludes patients with substantial immunity.

Liver-directed gene therapy requires hepatic monitoring for transaminase elevation requiring corticosteroid management.

Outcome data demonstrates substantial factor VIII increase, bleeding episode reduction and improved quality of life.

Symptoms

Severe hemophilia A presents with spontaneous joint and muscle bleeding requiring frequent factor VIII replacement.
Standard prophylaxis requires intravenous factor VIII infusions every 1-3 days creating substantial treatment burden.
Joint damage from repeated bleeding episodes causes hemophilic arthropathy with chronic pain and disability.
Inhibitor development to factor VIII complicates traditional therapy in subset of patients.
Quality of life substantially affected by bleeding episodes, prophylaxis requirements and disease complications.

Risk Factors

Pre-existing AAV5 neutralizing antibodies preclude gene therapy candidacy requiring screening.
Hepatic disease including viral hepatitis or cirrhosis may affect treatment safety and efficacy.
Pediatric population currently excluded from approved therapy with adult-only initial indication.
HIV infection generally contraindicated though may evolve with future evidence.
Active or recent factor VIII inhibitors may affect treatment response and safety considerations.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe hemophilia A patients on prophylaxis warrant gene therapy evaluation when criteria met.
  • Specialized hemophilia treatment center referral required for gene therapy delivery and management.
  • Post-infusion liver enzyme monitoring with weekly evaluation during initial 6 months.
  • Transaminase elevation triggers corticosteroid therapy with dose titration based on response.
  • Long-term follow-up monitors factor VIII durability, bleeding patterns and treatment-related complications.

Treatment Methods

01
Single intravenous infusion of valoctocogene roxaparvovec at 6 × 10^13 vector genomes per kg body weight.
02
Pre-treatment screening for AAV5 antibodies, hepatic function assessment and patient selection.
03
Post-infusion monitoring with weekly factor VIII activity and liver function testing during initial weeks.
04
Corticosteroid therapy with prednisone for transaminase elevation with dose adjustments based on response.
05
Comprehensive long-term care including bleeding pattern monitoring with reduced or eliminated factor concentrate use, joint health surveillance, regular factor VIII activity assessment, surveillance for late hepatic effects, vaccination considerations regarding AAV5 immunity for potential future re-treatment, integration with comprehensive hemophilia care including orthopedic, dental and physical therapy and patient education regarding ongoing care needs optimizes outcomes from this transformative therapy.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.